LAB
STANDARD BIOTOOLS INC.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeStandard BioTools reported Q2 2026 revenue decline of 7.6% YoY across all segments, while withdrawing full-year 2026 guidance due to the pending Treeline Biosciences merger. The company is actively restructuring through the sale of its Mass Cytometry business to Multiplex Bio and securing a $30 million Illumina payout, supported by strong liquidity of $541.1 million.
Red flags
- •Revenue declined 7.6% YoY in Q2 2026 with declines across all segments (consumables down 10%, instruments down 2%, services down 8%)
- •Full-year 2026 revenue guidance withdrawn, limiting investor visibility pending merger close
- •Divestiture of Mass Cytometry business signals strategic retreat from core product line
- •Reliance on one-time $30 million Illumina payment to strengthen balance sheet rather than organic growth
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Viking Global | SC 13D | +0 | 15.0% | -24.9% vs SPY -22.5% abs | 2026-06-12 | ↗ |
| Viking Global | SC 13G/A | — | 15.0% | -29.0% vs SPY -23.5% abs | 2026-05-15 | ↗ |